AstraZeneca PLC (AZN) Fundamental Analysis
AstraZeneca PLC is in a high-growth phase, expanding revenue 106% year-over-year as it scales. It is solidly profitable, with a latest net margin of 17%. Cash generation is healthy, funding the business from its own operations. On the latest filing the majority of indicators are constructive.
Beat Index assesses AstraZeneca PLC across sixteen analysis tabs, spanning revenue and income, margins, cash flow, returns, liquidity and leverage, working capital, intrinsic value, commitments, insider activity, risk, and its latest 20-F reads strongest on revenue growth, profit margins and cash generation while flagging balance-sheet strength for closer review. Every figure is taken as-reported from SEC EDGAR filings, with no vendor adjustments.
At a glance
- PositiveGrowth: Revenue up 106% YoY
- WatchBalance Sheet: Current ratio 0.9x (low debt, cash-generative)
- ConcernNo red flags in the latest quarter.
Trend matrix, last 4 quarters
| Dimension | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Growth | Revenue up 106% YoY | Revenue up 18% YoY | Revenue up 106% YoY | Revenue up 19% YoY |
| Profitability | Net margin 17% | Net margin 13% | Net margin 13% | Net margin 7% |
| Cash Generation | FCF margin 20% | FCF margin 18% | FCF margin 20% | FCF margin 20% |
| Balance Sheet | Current ratio 0.9x (low debt, cash-generative) | Current ratio 0.9x (low debt, cash-generative) | Current ratio 0.8x (low debt, cash-generative) | Current ratio 0.9x (low debt, cash-generative) |
Quarterly financials
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $58.74B | $54.07B | $45.81B | $44.35B | $37.42B |
| Cash & equivalents | $5.71B | $5.49B | $5.84B | $6.17B | $6.33B |
| Net income | $10.22B | $7.04B | $5.96B | $3.29B | $112.0M |
| Operating cash flow | $14.57B | $11.86B | $10.35B | $9.81B | $5.96B |
| Free cash flow | $11.77B | $9.94B | $8.98B | $8.72B | $4.87B |
Figures in USD, as reported to the SEC. Longer history is available in the full analysis.
What's inside the full dashboard
Sixteen analysis tabs, all sourced from SEC filings, no estimates.
- Cash Flow: Free cash flow generation and operating cash flow trends.
- Intrinsic Value: Discounted cash flow (DCF) valuation and enterprise multiples.
- Liquidity & Leverage: Balance-sheet strength: assets, liabilities, debt and liquidity ratios.
- Margins: Gross, operating, and net profit margin analysis.
- Returns: Return on equity, return on assets, and return on invested capital.
- Revenue & Income: Revenue growth, composition, and year-over-year income trends.
- Working Capital: Working-capital efficiency, cash conversion and asset-turnover metrics.
- Risk: Debt levels, liquidity ratios, and financial risk indicators.
- Insider: Insider stock transactions and executive activity.
- Commitments: Operating leases, purchase commitments, and future obligations.
To see more, create a free account.
Create free accountUnlock the full AstraZeneca PLC dashboard
Live valuation, management commentary, and peer comparison, all sourced directly from SEC filings. Free to access.